RT-induced release of the chemokine IL-8 was co-opted to drive the migration, antitumor efficacy, and persistence of CAR-T cells modified to express the cognate IL-8 receptors CXCR1 and CXCR2 in murine models of human glioma, breast, and pancreatic cancer [70]. The gene discussed is CXCL8; the disease is pancreatic neoplasm.